Safety and tolerability of first‐line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma

Abstract Background Advanced or metastatic esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis; new first‐line systemic treatment options are needed. Combining immuno‐oncology therapies with standard chemotherapy may represent a promising approach for the treatment of solid t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Dae Ho Lee, Hye Ryun Kim, Bhumsuk Keam, Ken Kato, Yasutoshi Kuboki, Haiyan Gao, Alejandro Yovine, Scott H. Robbins, Myung‐Ju Ahn
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2023-08-01
Edice:	Cancer Medicine
Témata:	chemotherapy clinical trials esophageal squamous cell immunology
On-line přístup:	https://doi.org/10.1002/cam4.6260
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!